報價延遲最少15分鐘:2024/05/17 00:49 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.43/0.94
|
|
企業價值
5.19B
|
| 資產負債 |
|
每股賬面淨值
2.20
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
396.59M
|
|
每股收益
2.25
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/17 00:49 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |